E24D233D-71BD-4EC2-A671-375917F24E5C
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.19185282522996
- age_years
- 53
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.644
- MYC_TARGETS_V1+0.620
- MYC_TARGETS_V2+0.589
- DNA_REPAIR+0.568
- G2M_CHECKPOINT+0.560
- MTORC1_SIGNALING+0.469
- OXIDATIVE_PHOSPHORYLATION+0.443
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.425
- GLYCOLYSIS+0.416
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.406
Top 10 suppressed
- KRAS_SIGNALING_DN-0.341
- BILE_ACID_METABOLISM-0.175
- UV_RESPONSE_DN-0.173
- MYOGENESIS-0.138
- HEDGEHOG_SIGNALING-0.129
- ESTROGEN_RESPONSE_EARLY-0.122
- APICAL_SURFACE-0.085
- SPERMATOGENESIS-0.081
- HEME_METABOLISM-0.040
- ANDROGEN_RESPONSE-0.037
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 541FDA8B-9FAE-4346-A6FD-C56735C87920 | — | — | 0.959 |
| 2 | 2E401C42-010F-4AFC-A362-B69426418626 | — | — | 0.957 |
| 3 | B99430AD-6309-4B90-A0AA-A5B2FA746246 | — | — | 0.954 |
| 4 | 242A2775-52C6-4B3C-9317-A27C32C92A6E | — | — | 0.953 |
| 5 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.942 |
| 6 | AFE5BFD1-AA9F-470A-A44F-341126F8057D | — | — | 0.941 |
| 7 | 61D1FD4D-F0FF-4D89-B26F-C1102685ED9D | — | — | 0.936 |
| 8 | EC1C727A-1F71-4C09-B867-7F163424D463 | — | — | 0.934 |
| 9 | D1729A17-148B-4C58-BEB5-7C4349A0E920 | — | — | 0.934 |
| 10 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.644 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.620 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.589 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.568 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.469 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.443 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.425 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.416 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.406 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.404 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.392 | Idelalisib | — uncovered |
| HYPOXIA | 0.376 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.354 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.354 | Inavolisib | — uncovered |
| COAGULATION | 0.326 | Binimetinib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.320 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.302 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.301 | Inavolisib | — uncovered |